Explore (New York, N.Y.) · 2025
The beneficial effects of the herbal medicine Di-Huang-Yin-Zi on patients with traumatic cauda equina injury: A randomized, double-blind, placebo-controlled study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Mei, Zu Pi-Zhen, Guo Li-Yang, Zhang Qing-Hua, Li Lian-Tao
Аннотация
OBJECTIVE: This study aimed to investigate the safety and efficacy of Di-Huang-Yin-Zi (DHYZ), also known as Rehmanniae Yin-Zi, a traditional Chinese medicinal formula used for treating of neurological disorders in patients with traumatic cauda equina injury (TCEI).
METHODS: In this double-blind, placebo-controlled study, TCEI patients with American Spinal Injury Association (ASIA) impairment grades C were randomized to receive either DHYZ (n = 30) or placebo (n = 30) for 8 weeks. Both groups also received rehabilitation therapy and oral mecobalamine therapy during the treatment. Motor and sensory functions, as well as walking ability, were assessed biweekly.
RESULTS: At the end of the treatment, the DHYZ group exhibited significantly higher scores in sensory and motor function, as well as walking ability, compared to the placebo group (all P < 0.05). Additionally, no serious side effects were reported.
CONCLUSION: DHYZ has the potential to accelerate nerve repair and may serve as an effective adjuvant therapy to enhance the recovery of nerve function in patients with TCEI.
METHODS: In this double-blind, placebo-controlled study, TCEI patients with American Spinal Injury Association (ASIA) impairment grades C were randomized to receive either DHYZ (n = 30) or placebo (n = 30) for 8 weeks. Both groups also received rehabilitation therapy and oral mecobalamine therapy during the treatment. Motor and sensory functions, as well as walking ability, were assessed biweekly.
RESULTS: At the end of the treatment, the DHYZ group exhibited significantly higher scores in sensory and motor function, as well as walking ability, compared to the placebo group (all P < 0.05). Additionally, no serious side effects were reported.
CONCLUSION: DHYZ has the potential to accelerate nerve repair and may serve as an effective adjuvant therapy to enhance the recovery of nerve function in patients with TCEI.